VANCOUVER, August 8, 2026, 07:08 PDT
- Shares ended Friday at $6.93 and then rose 9.7% to $7.60 in after-hours trading.
- Top-line data from the ABCL635 Phase 2 trial is expected ahead of the market open on Monday.
- Initial estimate: the after-hours change increased equity value by approximately $205 million.
AbCellera Biologics Inc. NASDAQ:ABCL advanced 9.7% in after-hours trade on Friday. The gain came after the company confirmed it will release ABCL635 Phase 2 results on Monday. Nasdaq will remain closed over the weekend.
The stock increase boosted AbCellera’s market value by an estimated $205 million. This figure is roughly 1.8 times higher than the $112 million in upfront payments disclosed from two recent partnership deals. The data implies that clinical validation is currently a stronger factor in valuation discussions than immediate deal proceeds.
The comparison does not represent a cash-flow projection. It illustrates the magnitude of Monday’s event premium.
| Friday valuation summary | Value |
|---|---|
| Close during regular session | $6.93 |
| Price after market hours | $7.60 |
| Change after hours | +$0.67, or 9.67% |
| Total shares outstanding | 306.61 million |
| Calculated increase in equity value | $205.4 million |
| Latest partnership immediate commitments | $112 million |
| Increase in market value relative to upfront commitments | 1.83 times |
Initial estimates are based on the stated share count and Friday’s after-market price. The $112 million figure reflects the total declared upfront payments, but does not represent the full cash amount collected in the quarter.
AbCellera will publish the data ahead of the opening bell on Monday. A call with management is scheduled for 7:30 a.m. Eastern Time. The placebo-controlled study involves roughly 80 postmenopausal women, tracking changes in both the frequency and severity of hot flashes.
The stock advanced 18.9% over the last five regular trading sessions, equalling the performance of Schrödinger Inc. NASDAQ:SDGR and outpacing other drug-discovery platform rivals. These figures do not reflect after-hours trading.
| Platform company | Friday close | Five-day move |
|---|---|---|
| AbCellera Biologics Inc. NASDAQ:ABCL | $6.93 | up 18.87% |
| Schrödinger Inc. NASDAQ:SDGR | $18.16 | up 18.85% |
| Absci Corp. NASDAQ:ABSI | $8.93 | up 12.61% |
| Recursion Pharmaceuticals Inc. NASDAQ:RXRX | $3.22 | up 1.26% |
Data provided by FactSet, as reported by MarketWatch.
Monday’s response may be influenced by positioning. The most recent disclosed short interest stood at 45.1 million shares, representing 19.1% of the float. These numbers are as of July 15 and do not reflect the most recent surge.
The operating quarter showed a significant decline. Revenue fell by 76% compared with the previous year. The net loss expanded by nearly 60%, and research expenses rose.
| Q2 financial comparison | 2026 | 2025 | Change |
|---|---|---|---|
| Revenue | $4.1 million | $17.1 million | -76.0% |
| Research and development | $46.0 million | $39.2 million | +17.3% |
| Sales, general and administrative | $13.9 million | $22.0 million | -36.8% |
| Net loss | $55.4 million | $34.7 million | Loss expanded by 59.7% |
| Loss per share | $0.18 | $0.12 | Loss per share increased 50.0% |
All amounts are in U.S. dollars. Company-reported results form the basis for percentage change calculations.
Some spending strain has been alleviated by recent agreements. Jazz Pharmaceuticals plc NASDAQ:JAZZ agreed to pay a total of $84 million upfront. Vertex Pharmaceuticals Inc. NASDAQ:VRTX contributed an additional $28 million. Together, these payments correspond to about half a year’s most recent net loss.
Jazz provided just $56 million of its pledged amount in the second quarter. An additional payment from Jazz is contingent on a third program commencing in the next 12 months. The company’s agreement with Vertex was disclosed after the quarter closed.
As of June 30, AbCellera reported holding over $565 million in cash and marketable securities. With additional government funding, total stated liquidity exceeded $675 million. According to management, this will cover at least three years of increased pipeline spending.
Chief Executive Carl Hansen stated on Wednesday, “We expect to announce top-line data very soon.” The timing is now set. The company said that positive Phase 2 data would justify advancing to a late-stage development program. investors.abcellera.com
Wall Street sentiment is positive ahead of the announcement. FactSet reported nine buy recommendations, with no holds or sells listed. The consensus target price stood at $10.75, with projections between $7 and $13.
| Analyst | Recommendation | Latest action | Target | Upside from $6.93 |
|---|---|---|---|---|
| Allison Bratzel, Piper Sandler | Buy | Maintained, Aug. 7 | $12 | 73.2% |
| Steven Seedhouse, Cantor Fitzgerald | Buy | Reiterated, Aug. 5 | $12 | 73.2% |
| Stephen Willey, Stifel | Buy | Maintained; target increased, Aug. 6 | $9 | 29.9% |
| Debanjana Chatterjee, JonesTrading | Buy | Maintained, July 29 | $13 | 87.6% |
Recent ratings and price objectives as listed by Google Finance.
Those targets could quickly become outdated on Monday. FactSet’s most conservative target, $7, is close to where shares settled on Friday. The current after-hours price is already above that, at $7.60.
ABCL575’s Phase 1 data is anticipated in the fourth quarter as the next internal milestone. ABCL386 and ABCL688 are projected to begin Phase 1/2 trials in 2027. Meanwhile, ABCL635 remains the key driver for short-term valuation.
Risks: The Phase 2 group size is limited, which may not resolve questions about durability. If the placebo-adjusted outcome is weak, much of the recent rally could be undone. Even robust results would still necessitate larger studies, increased investment, and eventual regulatory clearance.
Related articles: Biotechnology
